The Potential for Immunoconjugates in Lymphoma Therapy

Liu, Steven Y.; Press, Oliver W.

doi:10.1016/s0889-8588(05)70475-5

Cited by 11 publications

(4 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[8][9][10] Patients with other histologies (2 patients with small lymphocytic lymphoma) were not included in this comparative analysis of FL. Patients were eligible for the radioimmunotherapy trials if they were between the ages of 18 and 60 years, had progressive or persistent disease following conventional chemotherapy, had evidence of disease at the time of treatment, had acceptable organ function, and were otherwise considered candidates for transplantation by the primary treating physician.…”

Section: Selection Of Patients For Radioimmunotherapymentioning

confidence: 99%

“…8,13 Patients enrolled in the phase 1 trial received 0.35, 1.7, and 7 mg/kg tositumomab trace labeled with 131 I (185-370 MBq [5][6][7][8][9][10]) to evaluate biodistribution and to determine the optimal protein dose. Patients on the subsequent phase 2 trial received trace 131 I-labeled infusions at a dose of 1.7 mg/kg, which was estimated to be the optimal dose in phase 1 studies.…”

Section: Biodistribution Studiesmentioning

confidence: 99%

“…[8][9][10] FL is particularly radiosensitive, as indicated by long-term remissions in patients with localized disease when external beam radiotherapy alone is used for treatment. 11,12 With these observations in mind, we now have the opportunity to specifically evaluate the relative safety and efficacy of high-dose radioimmunotherapy (HD-RIT) versus conventional high-dose therapy (C-HDT) conditioning regimens in a nonrandomized cohort of patients with relapsed or refractory FL.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis

Gopal

Gooley

Maloney

et al. 2003

Blood

Self Cite

176

View full text Add to dashboard Cite

We performed a multivariable comparison of 125 consecutive patients with follicular lymphoma (FL) treated at our centers with either high-dose radioimmunotherapy (HD-RIT) using 131 I-anti-CD20 (n ‫؍‬ 27) or conventional high-dose therapy (C-HDT) (n ‫؍‬ 98) and autologous hematopoietic stem cell transplantation. estimated 5-year OS and PFS were 67% and 48%, respectively, for HD-RIT and 53% and 29%, respectively, for C-HDT. One hundred-day treatment-related mortality was 3.7% in the HD-RIT group and 11% in the C-HDT group. The probability of secondary myelodysplastic syndrome/ acute myeloid leukemia (MDS/AML) was estimated to be

show abstract

Section: Selection Of Patients For Radioimmunotherapymentioning

confidence: 99%

Section: Biodistribution Studiesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis

Gopal

Gooley

Maloney

et al. 2003

Blood

Self Cite

176

View full text Add to dashboard Cite

show abstract

“…It has long been clear in other areas of cancer therapeutics that successes are incremental, and usually come only after a long period of development. While there have been significant successes with vaccine approaches (6), adoptive T-cell therapy, and cytokines, it is instructive that monoclonal antibodies, such as Rituximab and Herceptin, have lately been most successful in clinical practice (7). Antibodies Are the demonstrated or theoretical mechanisms that cancer cells can use to escape immunologic destruction significant practical barriers for cancer treatment (1 l)?…”

Section: Introductionmentioning

confidence: 99%

The Status of Tumor Immunology and Cancer Immunotherapy

Sogn¹

2000

Immunological Investigations

View full text Add to dashboard Cite

Cellular and molecular themes in apoptosis

Alenzi

Warrens

2003

Wien Klin Wochenschr

View full text Add to dashboard Cite

Apoptosis, an active mechanism of cell death, is of central importance in many biological scenarios. Research in this area has the potential to contribute to our understanding of many diseases and raises several potential therapeutic opportunities. Given this potential and the speed with which our understanding of this field has advanced over recent years, it is timely to introduce the clinician to the background on which the clinical implications of this research will be built. This review begins with contrasting apoptosis with the other mechanism of cell death, necrosis, and then outlines the features by which apoptosis may be recognised. With a view to understanding the level at which this process may be involved in disease and therapeutics, it is important to be aware of the basic mechanistic features of the induction and execution of apoptosis. In this, surface molecules such as CD95 (Fas) and the cascade of intracellular enzymes involved at many levels in apoptosis, the caspases, are of central importance. In all this, the mitochondrion is crucial to the induction of apoptosis and the regulation of the whole process. In the last part of this review, we attempt to draw out the clinical relevance of all this information. It is clear that apoptosis has an important role in the pathophysiology of malignancy, particularly with respect to haematological cancers, but also other oncological diseases. Apoptosis is also very important in autoimmune disease and viral infection. Finally, it is clear that apoptosis may be manipulated therapeutically to the benefit of patients in various scenarios. This is clearly an exciting area for future development, but one which clearly depends on a thorough mechanistic understanding.

show abstract

The Potential for Immunoconjugates in Lymphoma Therapy

Cited by 11 publications

References 52 publications

High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis

High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis

The Status of Tumor Immunology and Cancer Immunotherapy

Cellular and molecular themes in apoptosis

Contact Info

Product

Resources

About